After more than 20 years operating in Bloomington, the North American arm of a major Danish hearing aid manufacturer is ...

GN in 2025 will double its space in the Twin Cities by moving from Bloomington to the Shakopee building once occupied by ...

Granite Telecommunications today celebrated the grand opening of its new state-of-the-art headquarters, marking a significant ...

IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today announced the appointment of Deirdre P. Connelly to its Board of Directors. Ms. Connelly is a ...

Moderna jolted investors by pushing back its profitability forecast two years, to 2028, and announcing a $1.1 billion cut in R&D spending.

During an investor presentation Thursday, executives admitted to being overly optimistic their vaccine could wrest significant market share away from GSK's and Pfizer's products this year.

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

7. Avadel did not provide details on a new action date. Sign up here. Healthcare & Pharmaceuticalscategory Rich nations have millions of mpox shots: Will they share with Africa? 10:48 AM UTC ...

Moderna on Thursday said it expects sales of between $2.5 billion and $3.5 billion next year, and forecast that new product launches would drive an average annual growth rate of 25% in revenue between ...

Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.